This study is testing if a combination of two medicines, DSP107 and atezolizumab, works better and is safer than fruquintinib for people with advanced colorectal cancer that is microsatellite stable (MSS) or mismatch repair-proficient (pMMR). These are specific types of colorectal cancer that have progressed after other treatments. You would be randomly assigned to receive either the DSP107 and atezolizumab combination or fruquintinib. Researchers will look at how long people live (overall survival) and how well the treatments work against the cancer. The goal is to find a better treatment option for this type of colorectal cancer.

Study design

This is a randomized, open-label study involving about 90 participants. You would be randomly assigned to one of two treatment groups.

What's involved

You would receive either DSP107 and atezolizumab intravenously, or fruquintinib orally, in 28-day cycles. The total time you spend in the study will depend on how you respond to treatment.

Compensation

Not stated in the trial record.

Follow-up

Researchers will track your overall survival from the first day of treatment until death, for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.